Form 4: Vor Biopharma Insider Sells Shares

Reprogrammed Interchange LLC, a 10% owner and director, sold over 37,000 shares of Vor Biopharma common stock in October 2025 under a Rule 10b5-1 plan.

Summary

• Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma Inc. (VOR), executed multiple sales of common stock.
• A total of 37,533 shares were sold across four transactions between October 17, 2025, and October 21, 2025.
• The sales were conducted at weighted average prices ranging from $30.0535 to $31.00 per share.
• Following these transactions, Reprogrammed Interchange LLC beneficially owns 1,166,909 shares of Vor Biopharma common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Reid Hoffman, who shares control over Reprogrammed Interchange LLC, may be deemed a beneficial owner but disclaims ownership except to the extent of his pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant insider selling by a 10% owner and director. While the sales were pre-planned under Rule 10b5-1, they still represent a reduction in stake by a key insider, which can be perceived as a bearish signal.

Negatives

• Significant insider selling by a 10% owner and director, Reprogrammed Interchange LLC, which could be perceived negatively by the market.
• The reduction in beneficial ownership by 37,533 shares indicates a decrease in the insider's stake in the company.

Risks

• Insider selling, even if pre-planned, can sometimes signal a lack of confidence in the company's near-term prospects or valuation by those with intimate knowledge.
• Potential for negative market sentiment or downward pressure on the stock price due to the reported sales.

Related Party Transactions

• Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma Inc., sold 37,533 shares of common stock. These transactions are considered related party dealings due to the reporting person's relationship with the issuer.

Stakeholder Impact

• Shareholders may interpret the insider selling as a negative signal regarding the company's future prospects or current valuation, potentially leading to decreased investor confidence.
• The sales could contribute to downward pressure on the stock price, affecting the value of existing shareholder investments.

Key Dates

Recommendation

While the insider sales by Reprogrammed Interchange LLC are a negative signal, the fact that they were executed under a Rule 10b5-1 plan suggests they were pre-scheduled and not necessarily indicative of new, adverse information. However, a reduction in stake by a 10% owner and director warrants caution. Investors should hold their positions and monitor future developments, particularly any further insider activity or company-specific news, before making significant investment decisions.

Keywords

Vor Biopharma, VOR, Insider Trading, Form 4, Stock Sale, Reprogrammed Interchange LLC, Reid Hoffman, 10b5-1 Plan